Form 10-Q - Quarterly report [Sections 13 or 15(d)]:
SEC Accession No. 0001641172-25-009724
Filing Date
2025-05-12
Accepted
2025-05-12 16:37:07
Documents
55
Period of Report
2025-03-31

Document Format Files

Seq Description Document Type Size
1 10-Q form10-q.htm   iXBRL 10-Q 817398
2 EX-31.1 ex31-1.htm EX-31.1 11609
3 EX-31.2 ex31-2.htm EX-31.2 12175
4 EX-32.1 ex32-1.htm EX-32.1 5703
  Complete submission text file 0001641172-25-009724.txt   4362350

Data Files

Seq Description Document Type Size
5 XBRL SCHEMA FILE zvsa-20250331.xsd EX-101.SCH 36932
6 XBRL CALCULATION FILE zvsa-20250331_cal.xml EX-101.CAL 35945
7 XBRL DEFINITION FILE zvsa-20250331_def.xml EX-101.DEF 149893
8 XBRL LABEL FILE zvsa-20250331_lab.xml EX-101.LAB 344084
9 XBRL PRESENTATION FILE zvsa-20250331_pre.xml EX-101.PRE 261033
57 EXTRACTED XBRL INSTANCE DOCUMENT form10-q_htm.xml XML 599012
Mailing Address 217 W. MAIN STREET SOMERVILLE NJ 08876
Business Address 217 W. MAIN STREET SOMERVILLE NJ 08876 908-370-5102
ZyVersa Therapeutics, Inc. (Filer) CIK: 0001859007 (see all company filings)

EIN.: 862685744 | State of Incorp.: DE | Fiscal Year End: 1231
Type: 10-Q | Act: 34 | File No.: 001-41184 | Film No.: 25935476
SIC: 2834 Pharmaceutical Preparations
(CF Office: 03 Life Sciences)